Suppr超能文献

一种天然生成的前列腺凋亡反应蛋白4诱饵可克服肿瘤的治疗抗性。

A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.

作者信息

Hebbar Nikhil, Burikhanov Ravshan, Shukla Nidhi, Qiu Shirley, Zhao Yanming, Elenitoba-Johnson Kojo S J, Rangnekar Vivek M

机构信息

Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky.

Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky.

出版信息

Cancer Res. 2017 Aug 1;77(15):4039-4050. doi: 10.1158/0008-5472.CAN-16-1970. Epub 2017 Jun 16.

Abstract

Primary tumors are often heterogeneous, composed of therapy-sensitive and emerging therapy-resistant cancer cells. Interestingly, treatment of therapy-sensitive tumors in heterogeneous tumor microenvironments results in apoptosis of therapy-resistant tumors. In this study, we identify a prostate apoptosis response-4 (Par-4) amino-terminal fragment (PAF) that is released by diverse therapy-sensitive cancer cells following therapy-induced caspase cleavage of the tumor suppressor Par-4 protein. PAF caused apoptosis in cancer cells resistant to therapy and inhibited tumor growth. A VASA segment of Par-4 mediated its binding and degradation by the ubiquitin ligase Fbxo45, resulting in loss of Par-4 proapoptotic function. Conversely, PAF, which contains this VASA segment, competitively bound to Fbxo45 and rescued Par-4-mediated induction of cancer cell-specific apoptosis. Collectively, our findings identify a molecular decoy naturally generated during apoptosis that inhibits a ubiquitin ligase to overcome therapy resistance in tumors. .

摘要

原发性肿瘤通常是异质性的,由对治疗敏感和新出现的耐药癌细胞组成。有趣的是,在异质性肿瘤微环境中对治疗敏感的肿瘤进行治疗会导致耐药肿瘤细胞凋亡。在本研究中,我们鉴定出一种前列腺凋亡反应-4(Par-4)氨基末端片段(PAF),它是在肿瘤抑制蛋白Par-4被治疗诱导的半胱天冬酶切割后,由多种对治疗敏感的癌细胞释放出来的。PAF可诱导对治疗耐药的癌细胞凋亡并抑制肿瘤生长。Par-4的一个VASA片段介导其与泛素连接酶Fbxo45的结合和降解,导致Par-4促凋亡功能丧失。相反,包含该VASA片段的PAF竞争性地与Fbxo45结合,并挽救Par-4介导的癌细胞特异性凋亡诱导。总的来说,我们的研究结果鉴定出一种在凋亡过程中自然产生的分子诱饵,它可抑制泛素连接酶以克服肿瘤的治疗耐药性。

相似文献

引用本文的文献

9
FBXO45 is a potential therapeutic target for cancer therapy.FBXO45是癌症治疗的一个潜在治疗靶点。
Cell Death Discov. 2020 Jul 3;6:55. doi: 10.1038/s41420-020-0291-2. eCollection 2020.

本文引用的文献

1
The influence of subclonal resistance mutations on targeted cancer therapy.亚克隆耐药突变对靶向癌症治疗的影响。
Nat Rev Clin Oncol. 2016 Jun;13(6):335-47. doi: 10.1038/nrclinonc.2015.175. Epub 2015 Oct 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验